
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical deve... MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.01 | -0.375939849624 | 2.66 | 2.79 | 2.54 | 4152 | 2.64129953 | CS |
4 | -0.18 | -6.36042402827 | 2.83 | 2.91 | 2.54 | 7247 | 2.77620443 | CS |
12 | -0.14 | -5.01792114695 | 2.79 | 2.91 | 2.3 | 21241 | 2.57235724 | CS |
26 | -0.46 | -14.7909967846 | 3.11 | 3.3339 | 2.3 | 32304 | 2.80286328 | CS |
52 | -1.7 | -39.0804597701 | 4.35 | 4.42 | 2.3 | 47309 | 3.22723775 | CS |
156 | -34.75 | -92.9144385027 | 37.4 | 44.038 | 2.3 | 1040095 | 10.76911271 | CS |
260 | -42.95 | -94.1885964912 | 45.6 | 91.5 | 2.3 | 1069424 | 31.08332656 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions